[161] Andrianov et al. (1998) *Biomaterials* 19:109-115.
[162] Payne et al. (1998) *Adv Drug Delivery Review* 31:185-196.
[163] Wong et al. (2003) *J Clin Pharmacol* 43(7):735-42.
[164] US2005/0215517.
[165] Thompson et al. (2003) *Methods in Molecular Medicine* 94:255-266.
[166] Kandimalla et al. (2003) *Nucleic Acids Research* 31:2393-2400.
[167] WO02/26757.
[168] WO99/62923.
[169] Krieg (2003) *Nature Medicine* 9:831-835.
[170] McCluskie et al. (2002) *FEMS Immunology and Medical Microbiology* 32:179-185.
[171] WO98/40100.
[172] U.S. Pat. No. 6,207,646.
[173] U.S. Pat. No. 6,239,116.
[174] U.S. Pat. No. 6,429,199.
[175] Kandimalla et al. (2003) *Biochemical Society Transactions* 31 (part 3):654-658.
[176] Blackwell et al. (2003) *J Immunol* 170:4061-4068.
[177] Krieg (2002) *Trends Immunol* 23:64-65.
[178] WO01/95935.
[179] Kandimalla et al. (2003) BBRC 306:948-953.
[180] Bhagat et al. (2003) BBRC 300:853-861.
[181] WO03/035836.
[182] WO01/22972.
[183] Thompson et al. (2005) *J Leukoc Biol* 78: 'The low-toxicity versions of LPS, MPL® adjuvant and RC529, are efficient adjuvants for CD4+ T cells'.
[184] UK patent application GB-A-2220211.
[185] WO94/21292.
[186] WO94/00153.
[187] WO95/17210.
[188] WO96/26741.
[189] WO93/19780.
[190] Gennaro (2000) *Remington: The Science and Practice of Pharmacy.* 20th edition, ISBN: 0683306472.
[191] Banzhoff (2000) *Immunology Letters* 71:91-96.
[192] Nony et al. (2001) *Vaccine* 27:3645-51.
[193] WO2005/089837.
[194] U.S. Pat. No. 6,692,468.
[195] WO00/07647.
[196] WO99/17820.
[197] U.S. Pat. No. 5,971,953.
[198] U.S. Pat. No. 4,060,082.
[199] EP-A-0520618.
[200] WO98/01174.
[201] Potter & Oxford (1979) *Br Med Bull* 35:69-75.
[202] Greenbaum et al. (2004) *Vaccine* 22:2566-77.
[203] Zurbriggen et al. (2003) *Expert Rev Vaccines* 2:295-304.
[204] Piascik (2003) *J Am Pharm Assoc (Wash DC).* 43:728-30.
[205] Mann et al. (2004) *Vaccine* 22:2425-9.
[206] Halperin et al. (1979) *Am J Public Health* 69:1247-50.
[207] Herbert et al. (1979) *J Infect Dis* 140:234-8.
[208] Chen et al. (2003) *Vaccine* 21:2830-6.

The invention claimed is:

1. An immunogenic composition comprising:
(i) a purified surface antigen, prepared from a cell culture-grown human influenza virus; and
(ii) an adjuvant comprising an oil-in-water emulsion, wherein the composition is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.

2. The composition of claim **1**, comprising purified surface antigens from more than one human influenza virus strain.

3. The composition of claim **2**, wherein the purified surface antigens are prepared from human influenza A virus and human influenza B virus.

4. The composition of claim **1**, wherein the purified surface antigen is from an H1 H2, H3, H5, H7 or H9 influenza A virus subtype.

5. The composition of claim **1**, wherein the composition contains from 0.1 to 20 μg of haemagglutinin per viral strain in the composition.

6. The composition of claim **1**, wherein the composition contains less than 10 ng of cellular DNA from the cell culture host, per 15 μg of haemagglutinin.

7. The composition of claim **1**, wherein the composition includes a 3-O-deacylated monophosphoryl lipid A.

8. A method for preparing an immunogenic composition comprising the steps of combining:
(i) a purified surface antigen, prepared from a cell culture-grown human influenza virus; and
(ii) an adjuvant comprising an oil-in-water emulsion, wherein the composition is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.

9. A kit comprising:
(i) a first kit component comprising a purified surface antigen, prepared from a cell culture-grown human influenza virus; and
(ii) a second kit component comprising an adjuvant comprising an oil-in-water emulsion, wherein the first kit component is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.

10. An immunogenic composition comprising:
(i) a purified surface antigen, prepared from a cell culture-grown human influenza virus; and
(ii) an adjuvant comprising an oil-in-water emulsion and a tocopherol, wherein the composition is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.

11. The composition of claim **10**, wherein the purified surface antigen is from an H1, H2, H3, H5, H7, or H9 influenza A subtype.

12. An immunogenic composition comprising:
(i) a purified surface antigen, prepared from a cell culture-grown virus; and
(ii) an adjuvant comprising an oil-in-water emulsion, wherein the composition is a trivalent vaccine comprising influenza antigens from one H1N1 influenza A strain, one H3N2 influenza A strain and one influenza B strain, wherein the composition is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.